ReviewCancers2022
Efficacy and Safety of Immunotherapy for Cervical Cancer-A Systematic Review of Clinical Trials.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Efficacy of pembrolizumab in advanced cancer of the vulva: a systematic review and single-arm meta-analysis.Frontiers in oncology · 2024Pooled it
- Breaking barriers in gynecologic malignancies with adoptive cell transfers and nanomedicine.Cell biomaterials · 2026Article
- Review
- Review
- Low pre-treatment neutrophil-to-lymphocyte ratio predicted a better survival in recurrent/metastatic cervical cancer treated with PD-1/PD-L1 inhibitors.Discover oncology · 2025Article
- Therapeutic Potential of IL-37 in Cervical Cancer: Suppression of Tumour Progression and Enhancement of CD47-Mediated Macrophage Phagocytosis.Molecular carcinogenesis · 2025Article
- The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology: a JAGO/NOGGO survey.BMC cancer · 2025Article
- HPV infection and the immune microenvironment in cervical cancer.Frontiers in immunology · 2025Review
- Article
- Nature of the Association between Rheumatoid Arthritis and Cervical Cancer and Its Potential Therapeutic Implications.Nutrients · 2024Review
- Systematic Review on the Effectiveness and Outcomes of Nivolumab Treatment Schemes in Advanced and Metastatic Cervical Cancer.Diseases (Basel, Switzerland) · 2024Review
- Identification of a new gene signature for prognostic evaluation in cervical cancer: based on cuproptosis-associated angiogenesis and multi-omics analysis.Cancer cell international · 2024Article
- Article
- Serum cell division cycle 42 reflects the treatment response and survival in patients with advanced cervical cancer who receive immune checkpoint inhibitor treatment.Oncology letters · 2023Article
- A Cellular Senescence-Related Signature Predicts Cervical Cancer Patient Outcome and Immunotherapy Sensitivity.Research square · 2023Article
- Review
- Review of the Standard and Advanced Screening, Staging Systems and Treatment Modalities for Cervical Cancer.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo systematically review the current body of evidence on the efficacy and safety of immunotherapy for cervical cancer (CC). MATERIAL AND
methodsMedline, the Cochrane Central Register of Controlled Trials and Web of Science were searched for prospective trials assessing immunotherapy in CC patients in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Full-text articles in English and German reporting outcomes of survival, response rates or safety were eligible.
resultsOf 4655 screened studies, 51 were included (immune checkpoint inhibitors (ICI)
conclusionStrong evidence on the efficacy of strategies to treat recurrent or metastatic cervical cancer is currently limited to pembrolizumab in combination with chemotherapy and bevacizumab, which substantiates an urgent need for large confirmatory trials on alternative immunotherapies. Overall, there is sound evidence on the safety of immunotherapy in CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.